drugset / Trial / NCT05605522
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of \[225Ac\]-FPI-2059 and \[111In\]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.
Timeline
- Start
- 2023-02-07
- Primary completion
- 2024-07-19
- Completion
- 2025-02-20
Outcome
Outcome not reported
Stopped: “Sponsor reprioritization of active trials.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [111In]-FPI-2058 | Diagnostic / imaging agent | — | Intravenous |
| Subject | [225]-FPI-2059 | Small molecule | — | Intravenous |